Details of the Drug Combinations

General Information of This Drug (ID: DMRICNP)

Drug Name
Vandetanib   DMRICNP
Synonyms
Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

920 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Vandetanib DC0K9QA ABIRATERONE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
ABIRATERONE + Vandetanib DCS8EE7 ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [2]
ABIRATERONE + Vandetanib DC44GG2 ABIRATERONE Glioma (Cell Line: SF-295) [2]
ABIRATERONE + Vandetanib DCBTQCE ABIRATERONE Glioma (Cell Line: SF-268) [2]
ABIRATERONE + Vandetanib DCQEXED ABIRATERONE Plasma cell myeloma (Cell Line: RPMI-8226) [2]
ABIRATERONE + Vandetanib DCK32G8 ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [3]
ABIRATERONE + Vandetanib DCCGAO0 ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
ABIRATERONE + Vandetanib DCY85DZ ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [4]
ABIRATERONE + Vandetanib DCVMT8A ABIRATERONE Melanoma (Cell Line: UACC-257) [4]
Cabazitaxel + Vandetanib DCZV0RR Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [2]
Cabazitaxel + Vandetanib DCNC3SP Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [2]
Cabazitaxel + Vandetanib DCYAJTA Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [2]
Cabazitaxel + Vandetanib DCA098B Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [2]
Cabazitaxel + Vandetanib DC3JOK7 Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Cabazitaxel + Vandetanib DCKCXZR Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [2]
Cabazitaxel + Vandetanib DCUEWSM Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Cabazitaxel + Vandetanib DCZLW10 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Cabazitaxel + Vandetanib DCGLL48 Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [2]
Cabazitaxel + Vandetanib DCKJTAO Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [2]
Cabazitaxel + Vandetanib DCYGJ0B Cabazitaxel Melanoma (Cell Line: MALME-3M) [2]
Cabazitaxel + Vandetanib DCEPSIO Cabazitaxel Melanoma (Cell Line: UACC-257) [2]
Cabazitaxel + Vandetanib DCBQQVP Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [2]
Cabazitaxel + Vandetanib DCOXC4I Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [2]
Cabazitaxel + Vandetanib DCJVPXC Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + Vandetanib DCB2ZQQ Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + Vandetanib DCQXPIB Crizotinib Astrocytoma (Cell Line: U251) [2]
Crizotinib + Vandetanib DCSSBOF Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + Vandetanib DC34IJY Crizotinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Epirubicin + Vandetanib DC98RZE Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Epirubicin + Vandetanib DC38THL Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
Epirubicin + Vandetanib DCHSKMU Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + Vandetanib DC4I39Q Epirubicin Colon carcinoma (Cell Line: KM12) [3]
Epirubicin + Vandetanib DC46DPE Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Epirubicin + Vandetanib DCVPWWP Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Epirubicin + Vandetanib DCP0FZB Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Epirubicin + Vandetanib DCH07J6 Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Epirubicin + Vandetanib DCHPBXS Epirubicin Melanoma (Cell Line: UACC-257) [4]
Epirubicin + Vandetanib DCNXNVP Epirubicin Melanoma (Cell Line: SK-MEL-2) [4]
Epirubicin + Vandetanib DCA1C69 Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Indazole derivative 5 + Vandetanib DCN4Z2F Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [2]
Indazole derivative 5 + Vandetanib DCSL84C Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [2]
Indazole derivative 5 + Vandetanib DCVG7P8 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Indazole derivative 5 + Vandetanib DCT79XR Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
Indazole derivative 5 + Vandetanib DCRLH3S Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Indazole derivative 5 + Vandetanib DCVEXM8 Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Indazole derivative 5 + Vandetanib DC9OKYI Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [4]
Indazole derivative 5 + Vandetanib DCXJSG8 Indazole derivative 5 Melanoma (Cell Line: UACC-257) [4]
Raloxifene + Vandetanib DCMIG0Z Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Raloxifene + Vandetanib DCGVGDH Raloxifene Adenocarcinoma (Cell Line: DU-145) [4]
Raloxifene + Vandetanib DCULBK8 Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Raloxifene + Vandetanib DCE6XO2 Raloxifene Melanoma (Cell Line: UACC-257) [4]
Ruxolitinib + Vandetanib DCUO9M9 Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Ruxolitinib + Vandetanib DCE0TXG Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Ruxolitinib + Vandetanib DCAHA17 Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Ruxolitinib + Vandetanib DCU8JDM Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Pentostatin DC5CROC Pentostatin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Pentostatin DCX1ZSJ Pentostatin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Pentostatin DCKWEFS Pentostatin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Pentostatin DCFTW0A Pentostatin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Fulvestrant DCGUPTC Fulvestrant Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Fulvestrant DCDUF6C Fulvestrant Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Fulvestrant DC4R0ZO Fulvestrant Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Gefitinib DC3W8NO Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Gefitinib DCRSHFK Gefitinib Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Gefitinib DCCIPNM Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Ruxolitinib DCDELCM Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Ruxolitinib DCZR86Y Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Hepzato DCD4Z53 Hepzato Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Dactinomycin DC42VOV Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Dactinomycin DCX8WRY Dactinomycin Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + Dactinomycin DC9YCD1 Dactinomycin Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Dactinomycin DCDMK1K Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Dactinomycin DCKKO1A Dactinomycin Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Dactinomycin DC7CFDY Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + Dactinomycin DCA4334 Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + DFN-15 DCWRJ3V DFN-15 Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + DFN-15 DCEFF28 DFN-15 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Lapatinib DC4T004 Lapatinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Crizotinib DCQH26D Crizotinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Cyclophosphamide DCHJTZ5 Cyclophosphamide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + LIAROZOLE DCTE1T1 LIAROZOLE Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Vismodegib DCJASU7 Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Isoniazid DCSJ5JU Isoniazid Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Vemurafenib DCJSGYE Vemurafenib Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Vemurafenib DC8F3HR Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Plicamycin DCMXU67 Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Plicamycin DC8EG5B Plicamycin Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + Plicamycin DC4MX92 Plicamycin Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Plicamycin DCFG64T Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Plicamycin DC1ZUME Plicamycin Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Plicamycin DCXL1JX Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Plicamycin DCSVKD2 Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Plicamycin DC075PN Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + Nilotinib DCORHX7 Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Nilotinib DCLTHTB Nilotinib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Thioguanine DCH2LA1 Thioguanine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Thioguanine DCMRAUT Thioguanine Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Thioguanine DCPCLRE Thioguanine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Thioguanine DCFL2UT Thioguanine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Triapine DC54MHH Triapine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Triapine DCMQLV9 Triapine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + ABIRATERONE DCZBK7S ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + ABIRATERONE DCMIGPZ ABIRATERONE Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + ABIRATERONE DCFLRD3 ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + ABIRATERONE DCCB80Z ABIRATERONE Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + 10-hydroxycamptothecin DCSS1WG 10-hydroxycamptothecin Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + Amonafide DCTMZSR Amonafide Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Terameprocol DCTW40Q Terameprocol Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Terameprocol DC8ZNPZ Terameprocol Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Terameprocol DCJL25C Terameprocol Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Terameprocol DCDSV79 Terameprocol Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + SCH 727965 DC526L0 SCH 727965 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Ifosfamide DC7HL3J Ifosfamide Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Ifosfamide DCMHOXJ Ifosfamide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Dexrazoxane DC2Y879 Dexrazoxane Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Docetaxel DC0J7WF Docetaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Docetaxel DCC4M9B Docetaxel Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + Raloxifene DCVYXDD Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Raloxifene DCEE2LU Raloxifene Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Raloxifene DCKH37N Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Raloxifene DC64N34 Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Raloxifene DCNRGWE Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Bendamustine hydrochloride DCGSGJY Bendamustine hydrochloride Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Bendamustine hydrochloride DC8IE6B Bendamustine hydrochloride Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Bendamustine hydrochloride DCTE6CM Bendamustine hydrochloride Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Trifluridine DCK8R5H Trifluridine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Trifluridine DC8I1CW Trifluridine Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Trifluridine DCXSGZG Trifluridine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Sirolimus DCSOXXS Sirolimus Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Sirolimus DCVBP3C Sirolimus Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + Sirolimus DCS7GZF Sirolimus Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Letrozole DCG2336 Letrozole Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Letrozole DCAT2GY Letrozole Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Mitomycin DC8G0E4 Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Mitomycin DCKNKR9 Mitomycin Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + Mitomycin DCYXEL5 Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Mitomycin DCD1CJX Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + SY-1425 DC2UXFS SY-1425 Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Uracil mustard DCCO64G Uracil mustard Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Uracil mustard DCI311E Uracil mustard Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Vincristine DCQ6T3N Vincristine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Arfolitixorin DCWMXHC Arfolitixorin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Arfolitixorin DC73R4L Arfolitixorin Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + Arfolitixorin DCRSWT7 Arfolitixorin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + BIO-300 DCGNJEC BIO-300 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + BIO-300 DCNZ1HL BIO-300 Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + BIO-300 DCJAPOL BIO-300 Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Altretamine DCV6QT3 Altretamine Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Altretamine DCYLAS0 Altretamine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Altretamine DCG8RH2 Altretamine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + TEM DCI3H85 TEM Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + TEM DC2ZCZN TEM Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + TEM DCN0F3L TEM Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + TEM DC368YM TEM Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Idarubicin DCXU3HF Idarubicin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Idarubicin DCEBMPJ Idarubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Indazole derivative 5 DC7W8WD Indazole derivative 5 Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Indazole derivative 5 DCYRDDQ Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Imatinib DCV78DD Imatinib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Bleomycin DC542BR Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Bleomycin DCJO42M Bleomycin Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Bortezomib DCWNKD6 Bortezomib Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Anastrozole DC9SKDB Anastrozole Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Anastrozole DCLMO9T Anastrozole Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Dacarbazine DCABH4F Dacarbazine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Dacarbazine DCBAVHJ Dacarbazine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Valrubicin DCDU964 Valrubicin Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Valrubicin DCPIY83 Valrubicin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Valrubicin DC0S521 Valrubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Topotecan DCPZ987 Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Topotecan DCPI7RJ Topotecan Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Topotecan DCB0YTR Topotecan Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Cabazitaxel DC8W77D Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Cabazitaxel DCFE45O Cabazitaxel Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + Epirubicin DCDU302 Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Epirubicin DCFJO2Z Epirubicin Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Epirubicin DCO1IBA Epirubicin Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Epirubicin DCMSMOY Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Epirubicin DCACGPO Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Cisplatin DCYVH5W Cisplatin Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Cisplatin DCTVBD4 Cisplatin Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Cisplatin DCAYAEY Cisplatin Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + ER819762 DCR2DP5 ER819762 Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + ER819762 DCTS8CY ER819762 Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Azacitidine DCS4QJT Azacitidine Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Azacitidine DCFU5G8 Azacitidine Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + Pomalidomide DCW2YWH Pomalidomide Colon carcinoma (Cell Line: KM12) [3]
Vandetanib + Pomalidomide DC383PG Pomalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Pomalidomide DCHPB47 Pomalidomide Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + Pomalidomide DCIJZTA Pomalidomide Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vandetanib + Taxol DCM02ZL Taxol Carcinoma (Cell Line: RXF 393) [3]
Vandetanib + PMID28870136-Compound-43 DCHNYWB PMID28870136-Compound-43 Carcinoma (Cell Line: MCF7) [3]
Vandetanib + Estramustine DC94MPY Estramustine Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vandetanib + Estramustine DC1T5R1 Estramustine Colon adenocarcinoma (Cell Line: COLO 205) [3]
Vandetanib + Estramustine DCC3OQA Estramustine Invasive ductal carcinoma (Cell Line: HS 578T) [3]
Vandetanib + Dasatinib DCBEG8M Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [3]
Vandetanib + Mechlorethamine DCT445E Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Mechlorethamine DCO73AM Mechlorethamine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Mechlorethamine DC7OVNJ Mechlorethamine Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Mechlorethamine DCEX87T Mechlorethamine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Pentostatin DCCH70O Pentostatin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Pentostatin DCMX7CK Pentostatin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Pentostatin DCWHKSH Pentostatin Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Pentostatin DC257UP Pentostatin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Pentostatin DCPWUJ8 Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Pentostatin DCPKOPK Pentostatin Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Pentostatin DCDT3XY Pentostatin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Fulvestrant DCB1U7K Fulvestrant Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + Fulvestrant DCBWOAU Fulvestrant Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Fulvestrant DCCBN2E Fulvestrant Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Fulvestrant DCEYZ4F Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Fulvestrant DCQHW3J Fulvestrant Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Fulvestrant DCOL5O1 Fulvestrant Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Fulvestrant DCC073A Fulvestrant Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Fulvestrant DCOYMGG Fulvestrant Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Fulvestrant DCS8OS3 Fulvestrant Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Fulvestrant DCMGQ0Q Fulvestrant Glioma (Cell Line: SF-268) [4]
Vandetanib + Fulvestrant DCAQW3W Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Fulvestrant DC6WD7X Fulvestrant Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Fulvestrant DCZNHES Fulvestrant Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Fulvestrant DCE5R9T Fulvestrant Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Gefitinib DCOQSAO Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + Gefitinib DC45NA3 Gefitinib Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Gefitinib DCE8Y87 Gefitinib Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Gefitinib DC1DLR7 Gefitinib Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Gefitinib DCR65IJ Gefitinib Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Gefitinib DCJ3ZN3 Gefitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Gefitinib DC5VZ1U Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Gefitinib DCO6H5B Gefitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Gefitinib DCWE7RY Gefitinib Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Gefitinib DCUIGWN Gefitinib Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Gefitinib DCZPNOM Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Gefitinib DC2KYK8 Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Gefitinib DCQOGJZ Gefitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Gefitinib DC7CYH5 Gefitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Gefitinib DC70PY9 Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Gefitinib DC4YN9X Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Gefitinib DC0HGN8 Gefitinib Glioma (Cell Line: SF-539) [4]
Vandetanib + Gefitinib DCO2FND Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vandetanib + Gefitinib DC4HZS9 Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Gefitinib DCRO3MC Gefitinib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vandetanib + Gefitinib DC7GFTN Gefitinib Malignant melanoma (Cell Line: UACC62) [4]
Vandetanib + Gefitinib DCK9P0P Gefitinib Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Gefitinib DC0II00 Gefitinib Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Gefitinib DC8SMH3 Gefitinib Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Gefitinib DC1646M Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Gefitinib DCE8WZG Gefitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Gefitinib DCID8TQ Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vandetanib + Gefitinib DCD76IS Gefitinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Ruxolitinib DCHMI2M Ruxolitinib Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Ruxolitinib DCX28F1 Ruxolitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Ruxolitinib DCJD7CA Ruxolitinib Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Ruxolitinib DC3GZ6Q Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Ruxolitinib DCOFCWS Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Ruxolitinib DCJZC0C Ruxolitinib Glioma (Cell Line: SF-268) [4]
Vandetanib + Ruxolitinib DCG7YNV Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Hepzato DCNBF07 Hepzato Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Hepzato DCU42TX Hepzato Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Hepzato DCU2R8N Hepzato Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Hepzato DCZLAGD Hepzato Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Ixabepilone DC6P6VQ Ixabepilone Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Ixabepilone DCB8BLP Ixabepilone Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Ixabepilone DCHP04P Ixabepilone Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Ixabepilone DCY6JUY Ixabepilone Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Dactinomycin DC2C93N Dactinomycin Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + Dactinomycin DCXSMS7 Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + Dactinomycin DCLJRPS Dactinomycin Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Dactinomycin DC7BUP2 Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Dactinomycin DCP57NJ Dactinomycin Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Dactinomycin DCU33X4 Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Dactinomycin DCSFDQO Dactinomycin Adenocarcinoma (Cell Line: HCT116) [4]
Vandetanib + Dactinomycin DCZNYIF Dactinomycin Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Dactinomycin DCRH0XR Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Dactinomycin DCIX1VA Dactinomycin Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Dactinomycin DC9FO52 Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Dactinomycin DCPGAXS Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Dactinomycin DCBCTBV Dactinomycin Astrocytoma (Cell Line: U251) [4]
Vandetanib + Dactinomycin DCK5ZH6 Dactinomycin Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Dactinomycin DCII7EL Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Dactinomycin DCLD97O Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Dactinomycin DCNBBO0 Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Dactinomycin DC7OAF4 Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Dactinomycin DC492HV Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Vandetanib + Dactinomycin DCW8WR1 Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Dactinomycin DC33OXX Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Dactinomycin DC4XZU7 Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Dactinomycin DCV1K6P Dactinomycin Glioblastoma (Cell Line: SNB-75) [4]
Vandetanib + Dactinomycin DCHAKXK Dactinomycin Glioma (Cell Line: SF-539) [4]
Vandetanib + Dactinomycin DCLPHIR Dactinomycin Glioma (Cell Line: SF-268) [4]
Vandetanib + Dactinomycin DCRIP4G Dactinomycin Glioma (Cell Line: SF-295) [4]
Vandetanib + Dactinomycin DCMOTYB Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vandetanib + Dactinomycin DCR5LRK Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Dactinomycin DCZ1RI8 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Dactinomycin DCGP1GM Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Dactinomycin DCIMQWK Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Dactinomycin DCEJZSL Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Dactinomycin DCDVA5S Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Dactinomycin DCZC3NY Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vandetanib + Dactinomycin DCEW6R5 Dactinomycin Malignant melanoma (Cell Line: UACC62) [4]
Vandetanib + Dactinomycin DCY1MLK Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Dactinomycin DCHUN2Z Dactinomycin Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Dactinomycin DCXKD7A Dactinomycin Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Dactinomycin DCGOXP8 Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Dactinomycin DCDYUGG Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Dactinomycin DCL44UT Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Dactinomycin DCO68HR Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Dactinomycin DCMEG9X Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Dactinomycin DCHZ4EA Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Dactinomycin DCGG4WB Dactinomycin Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Dactinomycin DCAOFKB Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + DFN-15 DCYXQPQ DFN-15 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + DFN-15 DCULRGO DFN-15 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + DFN-15 DCM9ORN DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + DFN-15 DCCW9DE DFN-15 Glioma (Cell Line: SF-268) [4]
Vandetanib + DFN-15 DCHKH6P DFN-15 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Lapatinib DCTHGJS Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Lapatinib DCJU5LU Lapatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + PMID28460551-Compound-2 DC0KO67 PMID28460551-Compound-2 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + PMID28460551-Compound-2 DCILISJ PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + PMID28460551-Compound-2 DCB4HLS PMID28460551-Compound-2 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Crizotinib DCDABXL Crizotinib Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Crizotinib DC0BRVR Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Crizotinib DCP4TRJ Crizotinib Astrocytoma (Cell Line: U251) [4]
Vandetanib + Crizotinib DCSINZ8 Crizotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Crizotinib DCW6BTG Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Crizotinib DC0K812 Crizotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Crizotinib DCOI8UN Crizotinib Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Cyclophosphamide DCSRJRE Cyclophosphamide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Cyclophosphamide DCTPAU3 Cyclophosphamide Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + LIAROZOLE DCQ01OU LIAROZOLE Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + LIAROZOLE DCHGR0Z LIAROZOLE Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Methotrexate DCR9TFG Methotrexate Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Methotrexate DCNJQD9 Methotrexate Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Vismodegib DC4S4TJ Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Vismodegib DCCX81Z Vismodegib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Vismodegib DCV0LXJ Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Vismodegib DCIW5GI Vismodegib Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Isoniazid DCC47IA Isoniazid Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Isoniazid DCI23QT Isoniazid Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Isoniazid DCWHA02 Isoniazid Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Isoniazid DCPSVSO Isoniazid Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Isoniazid DCJSPZJ Isoniazid Glioma (Cell Line: SF-268) [4]
Vandetanib + Isoniazid DCTTD03 Isoniazid Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Isoniazid DCQRN17 Isoniazid Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Arsenic trioxide DC1IZT9 Arsenic trioxide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Arsenic trioxide DCW52RL Arsenic trioxide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Vemurafenib DC2UZ7X Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Vemurafenib DCQ119I Vemurafenib Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Lenalidomide DCTY02U Lenalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Lenalidomide DCCHCUH Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Lenalidomide DC9FINR Lenalidomide Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Lenalidomide DCC509I Lenalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Plicamycin DC2KTUU Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + Plicamycin DC1RR2M Plicamycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Plicamycin DC2MQOI Plicamycin Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Plicamycin DC0N9PP Plicamycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Plicamycin DCYRQMC Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Plicamycin DC4A7V8 Plicamycin Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Plicamycin DCMGISY Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Plicamycin DC4V16Y Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Plicamycin DCRV7HJ Plicamycin Astrocytoma (Cell Line: U251) [4]
Vandetanib + Plicamycin DC16JX9 Plicamycin Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Plicamycin DCTSJJX Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Plicamycin DCU3OPO Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Plicamycin DCXJP64 Plicamycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Plicamycin DCX5T9P Plicamycin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Vandetanib + Plicamycin DC1CX8P Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Plicamycin DCESLPW Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Plicamycin DC9749A Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Plicamycin DCM0HO4 Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Plicamycin DC5ITWK Plicamycin Glioblastoma (Cell Line: SNB-75) [4]
Vandetanib + Plicamycin DCMCFDA Plicamycin Glioma (Cell Line: SF-268) [4]
Vandetanib + Plicamycin DC7VTDP Plicamycin Glioma (Cell Line: SF-295) [4]
Vandetanib + Plicamycin DCL880I Plicamycin Glioma (Cell Line: SF-539) [4]
Vandetanib + Plicamycin DCWYWBU Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Plicamycin DCLGCPM Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Plicamycin DC3CCR0 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vandetanib + Plicamycin DC8T1LI Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Plicamycin DCMN2WW Plicamycin Malignant melanoma (Cell Line: UACC62) [4]
Vandetanib + Plicamycin DCYWALF Plicamycin Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Plicamycin DCPUVQO Plicamycin Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Plicamycin DCSJF9W Plicamycin Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Plicamycin DCF0Q6H Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Plicamycin DCHXIWX Plicamycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vandetanib + Plicamycin DCIQWLL Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Plicamycin DCFBSJ0 Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Plicamycin DCAQR6T Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Plicamycin DCFH1B7 Plicamycin Renal cell carcinoma (Cell Line: UO-31) [4]
Vandetanib + Nilotinib DCA16JD Nilotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Nilotinib DCCKT5F Nilotinib Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Nilotinib DCSTYHL Nilotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Nilotinib DCIYXI9 Nilotinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Nilotinib DC4Y4RW Nilotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Nilotinib DC7YDL2 Nilotinib Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Nilotinib DCGK7UV Nilotinib Glioma (Cell Line: SF-268) [4]
Vandetanib + Nilotinib DCKP29A Nilotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Nilotinib DCLKO24 Nilotinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Thioguanine DCUQXKL Thioguanine Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + Thioguanine DCFOR1P Thioguanine Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Thioguanine DCJLPP4 Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Thioguanine DCSDH0C Thioguanine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Thioguanine DCJBO0K Thioguanine Astrocytoma (Cell Line: U251) [4]
Vandetanib + Thioguanine DCUBY3T Thioguanine Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Thioguanine DCINM2H Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Thioguanine DC3QS4G Thioguanine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Thioguanine DC9M9E4 Thioguanine Glioma (Cell Line: SF-295) [4]
Vandetanib + Thioguanine DCSXO09 Thioguanine Glioma (Cell Line: SF-268) [4]
Vandetanib + Thioguanine DC9KJ71 Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Thioguanine DCV2SS6 Thioguanine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vandetanib + Thioguanine DCGRZFS Thioguanine Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Thioguanine DCCZR9X Thioguanine Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Thioguanine DCQIAYL Thioguanine Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Thioguanine DCGC856 Thioguanine Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Thioguanine DCLKLWO Thioguanine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Thioguanine DCRP00L Thioguanine Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Triapine DCHAGX9 Triapine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Triapine DCC06QY Triapine Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Triapine DCGJLBZ Triapine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Triapine DC1EUX8 Triapine Glioma (Cell Line: SF-268) [4]
Vandetanib + Triapine DC9V67R Triapine Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + ABIRATERONE DC59VPU ABIRATERONE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + ABIRATERONE DCJHAV6 ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + ABIRATERONE DCMY0L9 ABIRATERONE Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + ABIRATERONE DCT741H ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + ABIRATERONE DCPBGJP ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + ABIRATERONE DCRSUFZ ABIRATERONE Melanoma (Cell Line: UACC-257) [4]
Vandetanib + ABIRATERONE DC80HS3 ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + 10-hydroxycamptothecin DC7UA8P 10-hydroxycamptothecin Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + 10-hydroxycamptothecin DC8C8K1 10-hydroxycamptothecin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + 10-hydroxycamptothecin DC1HNBI 10-hydroxycamptothecin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Topetecan DCVOLQX Topetecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Topetecan DC7P5K1 Topetecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Amonafide DCWFSCN Amonafide Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Amonafide DCUDB8C Amonafide Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Amonafide DCYXNG2 Amonafide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Amonafide DCJOUIH Amonafide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Amonafide DCYT4XJ Amonafide Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Pralatrexate DC1SNWR Pralatrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Pralatrexate DC08761 Pralatrexate Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Terameprocol DCPZ87G Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Terameprocol DCINSQ4 Terameprocol Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Terameprocol DC2EYRB Terameprocol Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Terameprocol DCFKAGU Terameprocol Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Terameprocol DC66YTU Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Terameprocol DCEH60K Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Terameprocol DCTGNHR Terameprocol Glioma (Cell Line: SF-268) [4]
Vandetanib + Terameprocol DCZ748W Terameprocol Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Terameprocol DCCXAN8 Terameprocol Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Terameprocol DCLO9Y4 Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + SCH 727965 DC8VZ9E SCH 727965 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Ifosfamide DCF8HCF Ifosfamide Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Ifosfamide DCXA71B Ifosfamide Glioma (Cell Line: SF-268) [4]
Vandetanib + Ifosfamide DCMLQPH Ifosfamide Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Ifosfamide DCS3ZJT Ifosfamide Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Ifosfamide DCN8ZBY Ifosfamide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Dexrazoxane DC5T7EG Dexrazoxane Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Dexrazoxane DC73WJG Dexrazoxane Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Dexrazoxane DCXDCG6 Dexrazoxane Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Dexrazoxane DC556PR Dexrazoxane Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Dexrazoxane DCT9YZV Dexrazoxane Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Dexrazoxane DCLEIU3 Dexrazoxane Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Dexrazoxane DCX5HF4 Dexrazoxane Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Docetaxel DC2M5NV Docetaxel Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Docetaxel DC6G4IM Docetaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Docetaxel DCBEPWP Docetaxel Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Docetaxel DCZZ3FG Docetaxel Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Docetaxel DCG6T53 Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Docetaxel DC9L3NY Docetaxel Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Docetaxel DC7QY1Z Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vandetanib + Docetaxel DCW7LVJ Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Docetaxel DCWFT5F Docetaxel Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vandetanib + Docetaxel DCY7M26 Docetaxel Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Docetaxel DC9PBT3 Docetaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Docetaxel DCM6K3Y Docetaxel Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Docetaxel DCPLE49 Docetaxel Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Raloxifene DCOZNSN Raloxifene Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Raloxifene DCI11V7 Raloxifene Adenocarcinoma (Cell Line: HCT116) [4]
Vandetanib + Raloxifene DCA0K7Q Raloxifene Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Raloxifene DCJMAXD Raloxifene Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Raloxifene DC0KNX7 Raloxifene Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Raloxifene DCQTURI Raloxifene Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Raloxifene DC2JVUW Raloxifene Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Raloxifene DCUHO7R Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Raloxifene DCHZQCY Raloxifene Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Raloxifene DCSPHPX Raloxifene Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Raloxifene DC8C86D Raloxifene Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Raloxifene DCSI7S2 Raloxifene Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Raloxifene DCDHSZV Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Raloxifene DCFS31C Raloxifene Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Raloxifene DC8P00M Raloxifene Clear cell renal cell carcinoma (Cell Line: A498) [4]
Vandetanib + Raloxifene DCAR30Y Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Raloxifene DCSHOF8 Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Raloxifene DCHTIKL Raloxifene Glioma (Cell Line: SF-268) [4]
Vandetanib + Raloxifene DC8WOE4 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Raloxifene DCJ2A28 Raloxifene High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vandetanib + Raloxifene DC87WQD Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Raloxifene DCZ3KAU Raloxifene Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Raloxifene DCBQVWI Raloxifene Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Raloxifene DCO1LRA Raloxifene Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Raloxifene DCFS4UA Raloxifene Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Raloxifene DCQA3ZR Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Raloxifene DC7LA5I Raloxifene Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Bendamustine hydrochloride DCLDPIA Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Bendamustine hydrochloride DC2A9TW Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Bendamustine hydrochloride DCO5G5L Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT116) [4]
Vandetanib + Bendamustine hydrochloride DC4N2LB Bendamustine hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Bendamustine hydrochloride DCGTLX4 Bendamustine hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Bendamustine hydrochloride DCQHST9 Bendamustine hydrochloride Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Bendamustine hydrochloride DCXUNAY Bendamustine hydrochloride Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Bendamustine hydrochloride DCPF9VR Bendamustine hydrochloride Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Bendamustine hydrochloride DC8B37G Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Bendamustine hydrochloride DC99CIK Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Bendamustine hydrochloride DCYC2Q9 Bendamustine hydrochloride Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Bendamustine hydrochloride DCG0Y4M Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Bendamustine hydrochloride DCKR8FU Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vandetanib + Bendamustine hydrochloride DC50HLW Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Bendamustine hydrochloride DCB2I4F Bendamustine hydrochloride Malignant melanoma (Cell Line: UACC62) [4]
Vandetanib + Bendamustine hydrochloride DC5UAN4 Bendamustine hydrochloride Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Bendamustine hydrochloride DCKZCIB Bendamustine hydrochloride Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Bendamustine hydrochloride DCTMSZ0 Bendamustine hydrochloride Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Bendamustine hydrochloride DCIM4G6 Bendamustine hydrochloride Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Trifluridine DCZD233 Trifluridine Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Trifluridine DCHVXK8 Trifluridine Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Trifluridine DCHQBUD Trifluridine Glioma (Cell Line: SF-539) [4]
Vandetanib + Trifluridine DC1KCWA Trifluridine Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Sirolimus DC7OVAO Sirolimus Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Sirolimus DCEBND3 Sirolimus Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Sirolimus DCX77QR Sirolimus Adenocarcinoma (Cell Line: HCT116) [4]
Vandetanib + Sirolimus DCS4XQS Sirolimus Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Sirolimus DCKWWCI Sirolimus Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Sirolimus DCAOUMQ Sirolimus Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Sirolimus DCG3ORA Sirolimus Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Sirolimus DCK8P1Y Sirolimus Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Sirolimus DC00LIL Sirolimus Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Sirolimus DC6KB2Z Sirolimus Clear cell renal cell carcinoma (Cell Line: A498) [4]
Vandetanib + Sirolimus DCI4Q9J Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Sirolimus DCUFNZN Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Sirolimus DCR47OI Sirolimus Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Sirolimus DC2VQW4 Sirolimus Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Sirolimus DC8NJBS Sirolimus Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Sirolimus DCTJ0H2 Sirolimus Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Sirolimus DCZA1WV Sirolimus Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Sirolimus DCW08WB Sirolimus Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Sirolimus DC7MSHR Sirolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vandetanib + Sirolimus DCJLSD2 Sirolimus Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Letrozole DC6OXI1 Letrozole Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Letrozole DC1AQT8 Letrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Letrozole DCX4X0G Letrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Letrozole DCAAN46 Letrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Letrozole DC9GV90 Letrozole Glioma (Cell Line: SF-268) [4]
Vandetanib + Letrozole DCF5JU8 Letrozole Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Letrozole DCA0G8O Letrozole Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Mitomycin DCRQ5T8 Mitomycin Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Mitomycin DCD55RN Mitomycin Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Mitomycin DCOEEYB Mitomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Mitomycin DCE2509 Mitomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Mitomycin DCEDT9V Mitomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Mitomycin DC91YM5 Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Mitomycin DC8X83B Mitomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Mitomycin DCYFGQI Mitomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Mitomycin DCS1OCE Mitomycin Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Mitomycin DCBI1IW Mitomycin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Mitomycin DC8HV0J Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + SY-1425 DCZWPA5 SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + SY-1425 DCHISNA SY-1425 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + SY-1425 DCLZLYI SY-1425 Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + SY-1425 DCV7334 SY-1425 Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + SY-1425 DCP1B4R SY-1425 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + SY-1425 DCF7QU4 SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + SY-1425 DCX9MYL SY-1425 Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Uracil mustard DCYWWXK Uracil mustard Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + Uracil mustard DCLB8JR Uracil mustard Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Uracil mustard DCUIPM1 Uracil mustard Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Uracil mustard DC1JE1J Uracil mustard Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Uracil mustard DC07BIT Uracil mustard Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Uracil mustard DC02A63 Uracil mustard Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Uracil mustard DCGSUCD Uracil mustard Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Uracil mustard DCX3BCR Uracil mustard Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Uracil mustard DCB2YG3 Uracil mustard Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Uracil mustard DCHWOHQ Uracil mustard Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Uracil mustard DCSD4RG Uracil mustard Glioblastoma (Cell Line: SNB-75) [4]
Vandetanib + Uracil mustard DC6GBZU Uracil mustard Glioma (Cell Line: SF-295) [4]
Vandetanib + Uracil mustard DCVM8R0 Uracil mustard Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Uracil mustard DCPP9MD Uracil mustard Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Uracil mustard DCLY8I5 Uracil mustard Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Uracil mustard DCGU6PU Uracil mustard Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Uracil mustard DC4XV0Z Uracil mustard Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vandetanib + Uracil mustard DC81DWQ Uracil mustard Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Uracil mustard DC7VXIS Uracil mustard Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Uracil mustard DCC2CDD Uracil mustard Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Uracil mustard DCFR8FQ Uracil mustard Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Uracil mustard DCZCZGO Uracil mustard Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Uracil mustard DCPZCFS Uracil mustard Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vandetanib + Uracil mustard DC2UEFW Uracil mustard Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Vincristine DC5JWCU Vincristine Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + Vincristine DCPU3GE Vincristine Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + Vincristine DCQLVFF Vincristine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Vincristine DCEK1VY Vincristine Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Vincristine DC5OBRW Vincristine Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vandetanib + Vincristine DCZ8EAP Vincristine Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Vincristine DCP3NTB Vincristine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Vincristine DC0WMT1 Vincristine Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Arfolitixorin DCGOR6M Arfolitixorin Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + Arfolitixorin DC3HX3D Arfolitixorin Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Arfolitixorin DC7ZY9E Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Arfolitixorin DCWB51A Arfolitixorin Astrocytoma (Cell Line: U251) [4]
Vandetanib + Arfolitixorin DCAMKT8 Arfolitixorin Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Arfolitixorin DC8OHG3 Arfolitixorin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Arfolitixorin DC1T2M6 Arfolitixorin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Arfolitixorin DC73HKI Arfolitixorin Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + BIO-300 DCJRHJW BIO-300 Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + BIO-300 DC5DAFB BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + BIO-300 DCQ0TM0 BIO-300 Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + BIO-300 DCJ8PI0 BIO-300 Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + BIO-300 DCSHWMM BIO-300 Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + BIO-300 DCFN6A0 BIO-300 Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + BIO-300 DC2II6Y BIO-300 Adenocarcinoma (Cell Line: HCT116) [4]
Vandetanib + BIO-300 DC0LBGX BIO-300 Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + BIO-300 DCLTYCS BIO-300 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + BIO-300 DCHCF7A BIO-300 Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + BIO-300 DC72BDY BIO-300 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + BIO-300 DCECMRV BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + BIO-300 DCHUYWQ BIO-300 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + BIO-300 DCMAUR4 BIO-300 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + BIO-300 DCLX3W4 BIO-300 Clear cell renal cell carcinoma (Cell Line: A498) [4]
Vandetanib + BIO-300 DCRVM8S BIO-300 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + BIO-300 DC20HZ6 BIO-300 Glioblastoma (Cell Line: SNB-75) [4]
Vandetanib + BIO-300 DCRY9UF BIO-300 Glioma (Cell Line: SF-539) [4]
Vandetanib + BIO-300 DCFOLF4 BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vandetanib + BIO-300 DCLNSBZ BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + BIO-300 DCF7P2N BIO-300 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + BIO-300 DCES9SL BIO-300 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + BIO-300 DCTP3ND BIO-300 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + BIO-300 DCVEIY9 BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + BIO-300 DC4IQGZ BIO-300 Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vandetanib + BIO-300 DC8N42H BIO-300 Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + BIO-300 DCQ0HB8 BIO-300 Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + BIO-300 DC4FEHL BIO-300 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + BIO-300 DCSBRCU BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + BIO-300 DCWYOQ0 BIO-300 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + BIO-300 DCXSFAC BIO-300 Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + BIO-300 DC0ZD4B BIO-300 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + BIO-300 DCDA9VU BIO-300 Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + BIO-300 DCTKM1J BIO-300 Renal cell carcinoma (Cell Line: UO-31) [4]
Vandetanib + BIO-300 DC231O1 BIO-300 Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Altretamine DCWDHH1 Altretamine Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Altretamine DC0TY8H Altretamine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Altretamine DC08O50 Altretamine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Altretamine DCDE4H5 Altretamine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Altretamine DC1KE8G Altretamine Glioma (Cell Line: SF-268) [4]
Vandetanib + Altretamine DCF087Y Altretamine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Altretamine DCPIJB1 Altretamine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Altretamine DCTM5G7 Altretamine Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Altretamine DCFNIAO Altretamine Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + TEM DCGOC9X TEM Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + TEM DC2KGMU TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + TEM DCQXQ1L TEM Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + TEM DC8Q0LC TEM High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + TEM DCGF3KY TEM Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + JNK-IN-8 DC365KS JNK-IN-8 Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + JNK-IN-8 DCW21YQ JNK-IN-8 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + JNK-IN-8 DC86MMQ JNK-IN-8 Glioma (Cell Line: SF-539) [4]
Vandetanib + JNK-IN-8 DC9MKHZ JNK-IN-8 Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + JNK-IN-8 DCDHR49 JNK-IN-8 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Idarubicin DCBF7MJ Idarubicin Glioblastoma? (Cell Line: T98G) [4]
Vandetanib + Idarubicin DCLT53M Idarubicin Glioma (Cell Line: SF-268) [4]
Vandetanib + Indazole derivative 5 DCXI2YP Indazole derivative 5 Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Indazole derivative 5 DCFO0GG Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Indazole derivative 5 DCUA68R Indazole derivative 5 Astrocytoma (Cell Line: U251) [4]
Vandetanib + Indazole derivative 5 DC7EDWT Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Indazole derivative 5 DCTSQ71 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Indazole derivative 5 DCT3457 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Indazole derivative 5 DC3FF5C Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Indazole derivative 5 DCMMZ1J Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Indazole derivative 5 DCQVZNQ Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Indazole derivative 5 DCP31KX Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Indazole derivative 5 DCQVFTK Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Indazole derivative 5 DC1SBKY Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Indazole derivative 5 DC38O51 Indazole derivative 5 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Indazole derivative 5 DCXUB7H Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Indazole derivative 5 DCSDTIK Indazole derivative 5 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Imatinib DCTWD4W Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Imatinib DCFVN2Y Imatinib Glioma (Cell Line: SF-268) [4]
Vandetanib + Imatinib DCXC1NC Imatinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Imatinib DCZ6V83 Imatinib Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Imatinib DC8TVFR Imatinib Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Bleomycin DCPLPMI Bleomycin Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Bleomycin DCEAIMB Bleomycin Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Bleomycin DC0NDF7 Bleomycin Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Bleomycin DCKFYR9 Bleomycin Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Bleomycin DCPU1BF Bleomycin Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Bleomycin DC1HJYQ Bleomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Bleomycin DCDXD6A Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Bleomycin DCZ85NY Bleomycin Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Bleomycin DCWDW4D Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Bleomycin DCLS3QE Bleomycin Clear cell renal cell carcinoma (Cell Line: A498) [4]
Vandetanib + Bleomycin DCJNWMV Bleomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Bleomycin DCRC964 Bleomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Bleomycin DCQK4N1 Bleomycin Glioma (Cell Line: SF-539) [4]
Vandetanib + Bleomycin DCV45FC Bleomycin Glioma (Cell Line: SF-295) [4]
Vandetanib + Bleomycin DCTGAJQ Bleomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Bleomycin DCINPM3 Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Bleomycin DCLUJ8N Bleomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Bleomycin DCB9YS4 Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Bleomycin DCRSRV7 Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Bleomycin DCQTCJ3 Bleomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Bleomycin DCREE1I Bleomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Bleomycin DCPJUIG Bleomycin Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Bortezomib DC54JQD Bortezomib Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Bortezomib DCN1TTG Bortezomib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Bortezomib DCNCCXB Bortezomib Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Bortezomib DCF6H71 Bortezomib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Bortezomib DCKOB5V Bortezomib Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Anastrozole DCAQ05L Anastrozole Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Anastrozole DCI9VH3 Anastrozole Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Anastrozole DCWI4UN Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Anastrozole DC93IKC Anastrozole Glioma (Cell Line: SF-295) [4]
Vandetanib + Anastrozole DCWCMHA Anastrozole Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Anastrozole DCC2EL3 Anastrozole Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Anastrozole DC7O41R Anastrozole Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Dacarbazine DCK05L6 Dacarbazine Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Dacarbazine DCR42HV Dacarbazine Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Dacarbazine DC25MHC Dacarbazine Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Dacarbazine DCO8K02 Dacarbazine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Dacarbazine DCX6OCA Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Dacarbazine DCUW97J Dacarbazine Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Dacarbazine DCXU8DI Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Dacarbazine DCQY3VV Dacarbazine Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Dacarbazine DC6KY4V Dacarbazine Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Dacarbazine DC2O6XD Dacarbazine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Dacarbazine DCT3Q09 Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Dacarbazine DCD4HFJ Dacarbazine Glioma (Cell Line: SF-295) [4]
Vandetanib + Dacarbazine DCVZ15S Dacarbazine Glioma (Cell Line: SF-268) [4]
Vandetanib + Dacarbazine DCPA6IV Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Dacarbazine DCZO1DM Dacarbazine Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Dacarbazine DC5ZSPW Dacarbazine Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Dacarbazine DC1K9J6 Dacarbazine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Dacarbazine DCLKD0G Dacarbazine Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Dacarbazine DCPICCI Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Dacarbazine DCOYBAI Dacarbazine Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Valrubicin DCP7J0N Valrubicin Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Valrubicin DCM5U40 Valrubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Valrubicin DCLI4RA Valrubicin Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Valrubicin DCPRMVI Valrubicin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Valrubicin DCJE0Z6 Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Valrubicin DCVB2HM Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Valrubicin DCWRBIQ Valrubicin Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Valrubicin DCDIA3C Valrubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Valrubicin DCA0EVL Valrubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Valrubicin DCEM20J Valrubicin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Topotecan DCLO0F7 Topotecan Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Topotecan DCONJA4 Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Topotecan DCMDN70 Topotecan Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Topotecan DCNG44A Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Topotecan DC4UJV2 Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Topotecan DCUWYGV Topotecan Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Topotecan DCQHZ5W Topotecan Glioma (Cell Line: SF-268) [4]
Vandetanib + Topotecan DCDXTRV Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Topotecan DCQT7GZ Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
Vandetanib + Topotecan DCWVQZI Topotecan Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Topotecan DCV2CSN Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Topotecan DCETUDQ Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Topotecan DCID18C Topotecan Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Topotecan DC38EKR Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Cabazitaxel DC0X1R9 Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Cabazitaxel DC8LN14 Cabazitaxel Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Cabazitaxel DCP50GB Cabazitaxel Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Cabazitaxel DCTQ1TZ Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Cabazitaxel DCGC051 Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [4]
Vandetanib + Cabazitaxel DC3OJJP Cabazitaxel Adenocarcinoma (Cell Line: SW-620) [4]
Vandetanib + Cabazitaxel DCAV0YX Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Cabazitaxel DCK8K1I Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Cabazitaxel DCT5RJ0 Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Cabazitaxel DCLM8YQ Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Cabazitaxel DCKLBD0 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Vandetanib + Cabazitaxel DCYDPAX Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Cabazitaxel DCNUFD8 Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Cabazitaxel DC0Z95E Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Cabazitaxel DCV68U6 Cabazitaxel Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Cabazitaxel DC2F8W2 Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Cabazitaxel DCQFZGP Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Cabazitaxel DCSGTS7 Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Epirubicin DCGDF41 Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Epirubicin DC4GD6E Epirubicin Astrocytoma (Cell Line: U251) [4]
Vandetanib + Epirubicin DCHCBZK Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Epirubicin DC04ZAW Epirubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vandetanib + Epirubicin DC7QPEM Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Epirubicin DCINPL5 Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Epirubicin DCVOAU1 Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Epirubicin DCFOMNA Epirubicin Glioma (Cell Line: SF-268) [4]
Vandetanib + Epirubicin DC3Z03J Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Vandetanib + Epirubicin DCADFLR Epirubicin Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Epirubicin DC7XRQC Epirubicin Melanoma (Cell Line: UACC-257) [4]
Vandetanib + Epirubicin DCEB7K7 Epirubicin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Epirubicin DCUTNDS Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Epirubicin DCIYBKB Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Cisplatin DCGEGCV Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Cisplatin DCB2BK0 Cisplatin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Cisplatin DCCFDTG Cisplatin Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Cisplatin DC9TM3S Cisplatin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Cisplatin DCKAF8B Cisplatin Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Sorafenib DCT4X3M Sorafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Romidepsin DC5FXKO Romidepsin Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Romidepsin DC0PRXQ Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Azacitidine DCQ4QTI Azacitidine Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Azacitidine DC71CMP Azacitidine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Azacitidine DCPJN6G Azacitidine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Azacitidine DCALBWU Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Azacitidine DCKLVO3 Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Azacitidine DCS4EH7 Azacitidine Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Azacitidine DCPY3TK Azacitidine Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Pomalidomide DCUSRBL Pomalidomide Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Pomalidomide DCEHVLW Pomalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Pomalidomide DCJAZMC Pomalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Pomalidomide DCFPZUE Pomalidomide Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Pomalidomide DCQ2KES Pomalidomide Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Pomalidomide DCGGN3O Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + Pomalidomide DCA3M3C Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Pomalidomide DCITFJ3 Pomalidomide Glioma (Cell Line: SF-268) [4]
Vandetanib + Pomalidomide DCUUHTW Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Pomalidomide DC6OCS1 Pomalidomide Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Pomalidomide DCVVVFV Pomalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Pomalidomide DCXIN86 Pomalidomide Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Vinflunine DCH11IR Vinflunine Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + Vinflunine DCXY22E Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + Vinflunine DC0DTE7 Vinflunine Adenocarcinoma (Cell Line: NCIH23) [4]
Vandetanib + Vinflunine DCENWOT Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Vinflunine DCCCZHC Vinflunine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Vinflunine DCZH8MS Vinflunine Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Vinflunine DCYC4Z7 Vinflunine Glioma (Cell Line: SF-295) [4]
Vandetanib + Vinflunine DCPXXW7 Vinflunine Glioma (Cell Line: SF-539) [4]
Vandetanib + Vinflunine DCC8RNT Vinflunine Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Vinflunine DC1KZWX Vinflunine Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + Mercaptopurine DCQJZ2Q Mercaptopurine Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + Mepacrine DCK6VJB Mepacrine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Taxol DCBY7UU Taxol Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Taxol DC57H7P Taxol Adenocarcinoma (Cell Line: HT29) [4]
Vandetanib + Taxol DC0YG8M Taxol Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + Taxol DCTZQ87 Taxol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Taxol DCSYUU9 Taxol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [4]
Vandetanib + Taxol DCSIMA0 Taxol Glioma (Cell Line: SF-295) [4]
Vandetanib + Taxol DCFM3T5 Taxol Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Taxol DC7A7SM Taxol Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Vandetanib + Taxol DC0A5ID Taxol Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Taxol DCX9SN2 Taxol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Taxol DCJVN97 Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Taxol DC4074P Taxol Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Taxol DCOOKA5 Taxol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Fludarabine DCAN2EL Fludarabine Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Fludarabine DCXDOKR Fludarabine Malignant melanoma (Cell Line: UACC62) [4]
Vandetanib + Fludarabine DCEVXPF Fludarabine Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + Fludarabine DCOC9SG Fludarabine Renal cell carcinoma (Cell Line: SN12C) [4]
Vandetanib + PMID28870136-Compound-43 DCMKRE2 PMID28870136-Compound-43 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + PMID28870136-Compound-43 DCBCAIJ PMID28870136-Compound-43 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + PMID28870136-Compound-43 DC3MC67 PMID28870136-Compound-43 Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + PMID28870136-Compound-43 DC5BMXP PMID28870136-Compound-43 Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + PMID28870136-Compound-43 DCGDNQM PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + PMID28870136-Compound-43 DC1WCNU PMID28870136-Compound-43 Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vandetanib + PMID28870136-Compound-43 DCX2985 PMID28870136-Compound-43 Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + FORMESTANE DCGJ81F FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [4]
Vandetanib + FORMESTANE DCGTBKX FORMESTANE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + FORMESTANE DCQCLQA FORMESTANE Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + FORMESTANE DCTH5TV FORMESTANE Amelanotic melanoma (Cell Line: M14) [4]
Vandetanib + FORMESTANE DCAIT8R FORMESTANE Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + FORMESTANE DCIWDOG FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + FORMESTANE DCXI4F7 FORMESTANE Glioma (Cell Line: SF-268) [4]
Vandetanib + FORMESTANE DCH8EK8 FORMESTANE Melanoma (Cell Line: MALME-3M) [4]
Vandetanib + FORMESTANE DCRGCYH FORMESTANE Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + FORMESTANE DCY5AKK FORMESTANE Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Aminolevulinic Acid Hydrochloride DCR87ST Aminolevulinic Acid Hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Estramustine DC3OTLI Estramustine Adenocarcinoma (Cell Line: HCC-2998) [4]
Vandetanib + Estramustine DCOXLDW Estramustine Adenocarcinoma (Cell Line: HCT116) [4]
Vandetanib + Estramustine DCD282M Estramustine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [4]
Vandetanib + Estramustine DCCV0ZG Estramustine Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
Vandetanib + Estramustine DC4HAKY Estramustine Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Estramustine DCLAZXW Estramustine Astrocytoma (Cell Line: SNB-19) [4]
Vandetanib + Estramustine DCU5RJ2 Estramustine Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
Vandetanib + Estramustine DCAA1BJ Estramustine Glioma (Cell Line: SF-268) [4]
Vandetanib + Estramustine DCHNO8T Estramustine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Estramustine DC8ETU5 Estramustine Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + Estramustine DC3DI5Z Estramustine Melanoma (Cell Line: SK-MEL-2) [4]
Vandetanib + Estramustine DCEBV1D Estramustine Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Estramustine DC86089 Estramustine Plasma cell myeloma (Cell Line: RPMI-8226) [4]
Vandetanib + Digitoxin DCMNLFS Digitoxin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vandetanib + Digitoxin DCFDU8Z Digitoxin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Busulfan DCFLYLZ Busulfan Anaplastic large cell lymphoma (Cell Line: SR) [4]
Vandetanib + Dasatinib DC4PPVB Dasatinib Adenocarcinoma (Cell Line: DU-145) [4]
Vandetanib + Dasatinib DCWF94E Dasatinib Adenocarcinoma (Cell Line: A549) [4]
Vandetanib + Dasatinib DCK78E9 Dasatinib Astrocytoma (Cell Line: U251) [4]
Vandetanib + Dasatinib DCPW8MY Dasatinib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + Dasatinib DC1TZL7 Dasatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [4]
Vandetanib + Dasatinib DC77FDE Dasatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [4]
Vandetanib + Dasatinib DCHVBO8 Dasatinib Glioma (Cell Line: SF-268) [4]
Vandetanib + Dasatinib DC1QVP9 Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
Vandetanib + Dasatinib DC0Z9M2 Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vandetanib + Dasatinib DCJZ1TI Dasatinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
Vandetanib + Dasatinib DCHFNKX Dasatinib Lung adenocarcinoma (Cell Line: EKVX) [4]
Vandetanib + Dasatinib DCELTOI Dasatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
Vandetanib + Dasatinib DC0FS0P Dasatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
Vandetanib + Dasatinib DCF61KY Dasatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
Vandetanib + Dasatinib DCMSHIR Dasatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vandetanib + Dasatinib DCSGR37 Dasatinib Papillary renal cell carcinoma (Cell Line: ACHN) [4]
Vandetanib + Dasatinib DCNT9ZE Dasatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Vandetanib + Dasatinib DC2ARX8 Dasatinib Prostate carcinoma (Cell Line: PC-3) [4]
Vandetanib + Dasatinib DC0PI67 Dasatinib Renal cell carcinoma (Cell Line: UO-31) [4]
Vemurafenib + Vandetanib DC3MIC9 Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vemurafenib + Vandetanib DCD6FFS Vemurafenib Adenocarcinoma (Cell Line: HT29) [4]
Vemurafenib + Vandetanib DCYIFTC Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vemurafenib + Vandetanib DCJ3BCN Vemurafenib Astrocytoma (Cell Line: U251) [4]
Vemurafenib + Vandetanib DCLSUE4 Vemurafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vemurafenib + Vandetanib DCY53QY Vemurafenib Melanoma (Cell Line: UACC-257) [4]
Vemurafenib + Vandetanib DCDJOXP Vemurafenib Melanoma (Cell Line: SK-MEL-2) [4]
Vismodegib + Vandetanib DCITY3O Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vismodegib + Vandetanib DC69VVF Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [3]
Vismodegib + Vandetanib DCDJS6F Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [4]
Vismodegib + Vandetanib DCMUGPW Vismodegib Amelanotic melanoma (Cell Line: M14) [4]
Vismodegib + Vandetanib DCFYUCD Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [4]
Vismodegib + Vandetanib DCAF6KV Vismodegib Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
Vismodegib + Vandetanib DC969PV Vismodegib Glioma (Cell Line: SF-268) [4]
Vismodegib + Vandetanib DC50J8E Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 920 DrugCom(s)
16 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Anastrozole + Vandetanib DCSZ9D8 Anastrozole Breast Cancer [5]
Bortezomib + Vandetanib DCFX0HE Bortezomib Medullary Thyroid Carcinoma [6]
Docetaxel + Vandetanib DCB58HH Docetaxel Non-small Cell Lung Cancer [7]
Docetaxel + Vandetanib DCSTJFP Docetaxel Advanced Breast Cancer [8]
Everolimus + Vandetanib DC9I00B Everolimus Advanced Malignant Neoplasm [9]
Gemcitabine + Vandetanib DCHRXVN Gemcitabine Malignant Solid Tumour [10]
Metformin + Vandetanib DCPCRU5 Metformin Renal Cell Carcinoma [11]
Omeprazole + Vandetanib DC5L4RV Omeprazole Medullary Thyroid Cancer [12]
Pemetrexed + Vandetanib DCIIQRJ Pemetrexed Non Small Cell Lung Cancer [13]
Pemetrexed + Vandetanib DCY7CA6 Pemetrexed Carcinoma [14]
Ranitidine + Vandetanib DCRLAF7 Ranitidine Medullary Thyroid Cancer [12]
Temozolomide + Vandetanib DCG1SIA Temozolomide Glioblastoma Multiforme [15]
Vandetanib + Bicalutamide DC5N9RD Bicalutamide Prostate Cancer [16]
Cabozantinib + Vandetanib DC6PJ87 Cabozantinib Thyroid Cancer [17]
Fulvestrant + Vandetanib DC4REQD Fulvestrant Neoplasms [18]
Cabozantinib + Vandetanib DCENZFR Cabozantinib Medullary Thyroid Cancer [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
5 ClinicalTrials.gov (NCT00481845) Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer
6 ClinicalTrials.gov (NCT00923247) A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)
7 ClinicalTrials.gov (NCT00312377) ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
8 ClinicalTrials.gov (NCT00494481) E3 Breast Cancer Taxotere Combination
9 ClinicalTrials.gov (NCT01582191) Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
10 ClinicalTrials.gov (NCT00551096) Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
11 ClinicalTrials.gov (NCT02495103) Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
12 ClinicalTrials.gov (NCT01539655) Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
13 ClinicalTrials.gov (NCT00418886) Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
14 ClinicalTrials.gov (NCT00506051) ZD6474(Vandetanib) + Alimta Combo Study
15 ClinicalTrials.gov (NCT00441142) Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
16 ClinicalTrials.gov (NCT00659438) Efficacy and Safety of Zactima?in Patients With Castration-refractory Metastatic Prostate Cancer
17 ClinicalTrials.gov (NCT03630120) Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
18 ClinicalTrials.gov (NCT02530411) Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer
19 ClinicalTrials.gov (NCT04760288) A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).